Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Biomarkers

Hereditary Breast and Ovarian Cancer Syndrome

How Biomarkers Are Changing Lung Cancer Care
Many biologic markers (biomarkers) are known to drive cancer and its progression, allowing scientists to develop new medications to target those biomarkers and increase survival for patients with lung cancer. Read More ›

Immunotherapy Beneficial in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC. Read More ›

New Study Shows Causes of Lung Cancer in People Who Never Smoked
It has become increasingly clear that lung cancer can be caused by different factors, including some environmental chemicals. Lung cancer in never smokers under the microscope. Read More ›

Biomarker Testing Is Driving the Development of New Therapies
Non-Hodgkin lymphoma survivor Dan Dean spoke with several experts about the advances in genomic testing, which have enabled oncologists to treat patients with new “targeted therapies” that fight cancer based on the specific features of a tumor. Read More ›

Immunotherapy Brings New Hope for Patients with Non–Small-Cell Lung Cancer and PD-1/PD-L1 Biomarker
Two experts discuss the advances made in lung cancer with the introduction of new immunotherapies, which have extended life for patients, and why testing for biomarkers is crucial. Read More ›

FDA Approved Xalkori for Young Patients with Anaplastic Large-Cell Lymphoma and ALK Mutation
In January 2021, the FDA approved a new indication for Xalkori (crizotinib), an oral ALK inhibitor, for the treatment of young patients who are diagnosed with relapsed or refractory systemic anaplastic large-cell lymphoma and ALK mutation. Xalkori was previously approved for metastatic lung cancer and ALK or ROS1 mutation. Read More ›

New Therapies Improve Survival in Patients with Lung Cancer Associated with a Biomarker
At the October 2020 conference of the European Society for Medical Oncology (ESMO), researchers presented information on new or recently approved targeted therapies and immunotherapies for lung cancer. Read More ›

Tabrecta Approved for NSCLC with MET Biomarker
In May 2020, the FDA approved Tabrecta, a new targeted therapy for the treatment of patients with metastatic non–small-cell lung cancer that is associated with the MET biomarker. Read More ›

Biomarker Testing in Non–Small-Cell Lung Cancer: A Guide for Patients

Non–small-cell lung cancer, or NSCLC, is the most common form of lung cancer, accounting for about 80% to 85% of all lung cancer cases in the United States.

Read More ›

Page 1 of 3